Trajectories of infection, vaccination and antibody response to SARS-CoV-2 in adults: a cohort study in Catalonia | BMC Medicine
Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses after COVID-19 vaccination in 212,102 people. Common Nat. 2022;13:907.
Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G, et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022;75:103805.
Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody responses and correlates of protection in the general population after two doses of ChAdOx1 or BNT162b2 vaccines. Nat Med 2022. https://doi.org/10.1038/s41591-022-01721-6.
Dashdorj NJ, Wirz OF, Röltgen K, Haraguchi E, Buzzanco AS, Sibai M, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell host microbe. 2021;29:1738–1743.e4.
Ruggiero A, Piubelli C, Calciano L, Accordini S, Valenti MT, Carbonare LD, et al. Vaccination against SARS-CoV-2 elicits unconventional specific IgM responses in naïve and previously infected individuals with COVID-19. EBioMedicine. 2022;77:103888.
Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucous Immunol. 2022. https://doi.org/10.1038/s41385-022-00511-0.
Dobaño C, Jiménez A, Rubio R, Alonso S, Ramírez-Morros A, Vidal M, et al. Spike-based COVID-19 immunization increases antibodies to core antigen. Translation Res. 2022;240:26–32.
Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does SARS-CoV-2 infection or vaccination result in long-lasting immunity? Respir Med lancet. 2021;9:1450–66.
Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Declining immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. eBioMedicine. 2022;77:103904.
Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC, Marconi VC, et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization – Five Veterans Affairs Medical Centers, USA, February 1-August 6, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1294–9.
Karachaliou M, Moncunill G, Espinosa A, Castaño-Vinyals G, Jiménez A, Vidal M, et al. Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain. Sci Rep. 2021;11:21571.
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decline of anti-SARS-CoV-2 antibodies in people with mild Covid-19. N Engl J Med. 2020;383:1085–7.
Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:e00084–18.
Obón-Santacana M, Vilardell M, Carreras A, Duran X, Velasco J, Galván-Femenía I, et al. GCAT|Genomes for life: a prospective cohort study of genomes from Catalonia. BMJ open. 2018;8:e018324.
Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of anti-SARS-CoV-2 antibodies and the role of pre-existing antibodies against human coronaviruses. Common Nat. 2021;12:4740.
Dobaño C, Santano R, Jiménez A, Vidal M, Chi J, Rodrigo Melero N, et al. Immunogenicity and cross-reactivity of antibodies against SARS-CoV-2 nucleocapsid protein: utility and limitations in seroprevalence and immunity studies. Transl Res J Lab Clin Med. 2021. https://doi.org/10.1016/j.trsl.2021.02.006.
ECDC. Variants of interest and concern in the EU/EEA.
Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A, and G against SARS-CoV-2 antigens. J Clin Microbiol. 2021;59.
Catalan Ministry of Health. Catalan Ministry of Health Catalan Epidemiological Surveillance System.
Gerussi V, Peghin M, Palese A, Bressan V, Visintini E, Bontempo G, et al. Vaccination reluctance in Italian patients recovered from COVID-19 infection towards influenza and Sars-Cov-2 vaccination. Vaccines. 2021;9:172.
Nguyen LH, Joshi AD, Drew DA, Merino J, Ma W, Lo CH, et al. Self-reported COVID-19 vaccine hesitancy and uptake among participants of different racial and ethnic groups in the US and UK. Common Nat. 2022;13:636.
Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022;25:103743.
Dobaño C, Ramírez-Morros A, Alonso S, Vidal-Alaball J, Ruiz-Olalla G, Vidal M, et al. Persistence and basic determinants of seropositivity and reinfection rates among healthcare workers up to 12.5 months after COVID-19. BMC Med. 2021;19:155.
Faro-Viana J, Bergman ML, Gonçalves LA, Duarte N, Coutinho TP, Borges PC, et al. Population homogeneity for the antibody response to the COVID-19 BNT162b2/Comirnaty vaccine is only achieved after the second dose in all adult age groups. Common Nat. 2022;13:140.
Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijočević H, et al. Dynamics of spike- and nucleocapsid-specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Common Nat. 2022;13:153.
Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Jabal KA, et al. Association between vaccination status and reported incidence of post-acute symptoms of COVID-19 in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. preprint. Epidemiology; 2022.
Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Risk factors for long COVID: analyzes of 10 longitudinal studies and electronic health records in the UK. preprint. Epidemiology. 2021.
Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection among UK users of the COVID Symptom Study app: a prospective, community-based, nested case-control study. Lancet Infect Dis. 2022;22:43–55.
Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection results in a robust humoral response and antibodies that effectively neutralize the variants. Sci Immunol. 2022;7:eabn8014.
Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can baseline predict outcome? Immunol Trends. 2020;41:457–65.
Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparison of clinical effectiveness of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11:22777.
Lafon E, Jäger M, Bauer A, Reindl M, Bellmann-Weiler R, Wilflingseder D, et al. Comparative analyzes of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. J Allergy Clin Immunol. 2022;149:1242–1252.e12.
Fraussen J. IgM responses following vaccination against SARS-CoV-2: overview of protective and pre-existing immunity. eBioMedicine. 2022;77:103922.
Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13:eabd2223.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven third-dose (booster) COVID-19 vaccines after two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomized, controlled phase 2 trial. Lancet. 2021;398:2258–76.
Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adult UK general population. Nat Microbiol. 2021;6:1140–9.
Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Heterogeneity of age-related immune response to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–22.
Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, et al. Effects of age, sex, serological status and underlying comorbidities on humoral response after Pfizer-BioNTech mRNA vaccination after SARS-CoV-2: a systematic review. Crit Rev Clin Lab Sci. 2022;1–18.
Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The effect of smoking on the humoral response to COVID-19 vaccines: a systematic review of epidemiological studies. Vaccines. 2022;10:303.
Mazereel V, Van Assche K, Detraux J, De Hert M. COVID-19 vaccination for people with severe mental illness: why, what and how? Lancet Psychiatry. 2021;8:444–50.
Naruse H, Ito H, Izawa H, Sarai M, Ishii J, Sakaguchi E, et al. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease. J Clin Med. 2021;10:5498.
Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: no association with age, gender, obesity and adverse effects. Immunol before. 2021;12:779212.